Liminal BioSciences Inc. LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

NDAQ:LMNL - Post by User

Liminal BioSciences Inc. > NR : FDA accepts LMNL's BLA (Riplazym)

<< Previous

Bullboard Posts

Next >>

Comment by GunnerGon Sep 21, 2020 4:42pm

68 Views

Post# 31592811

RE:RE:NR : FDA accepts LMNL's BLA (Riplazym)

care to provide a link to thiis public data?

See Aldo, this is how it starts.

eric40 wrote: This is very good news. Now it is a matter of time to get the BLA.

Public data from the FDA over the last 20 years shows that resubmission of a BLA/NDA after CMC issues brought a BLA acceptance very fast, in much less than 6 months, many within in 1 to 2 months from resubmissiom.

GLTA